Literature DB >> 20119577

Pulmonary toxicity after a quick course of combinatorial vincristine, bleomycin, and cisplatin neoadjuvant chemotherapy in cervical cancer.

Kyung-Do Ki1, Jong-Min Lee, Seon-Kyung Lee, Seo-Yun Tong, Chu-Yeop Huh, Jung-Kyu Ryu, Kyo-Young Kim.   

Abstract

Pulmonary toxicity is one of the most serious adverse effects associated with a quick course of vincristine, bleomycin, and cisplatin neoadjuvant chemotherapy (NAC-VBP). The aim of this study was to evaluate pulmonary toxicity related to a quick course NAC-VBP. A total of consecutive 61 patients, who underwent at most 3 cycles of NAC-VBP every 10 days in the International Federation of Gynecology and Obstetrics (FIGO) stage IB-IIB cervical cancer from 1995 to 2007, were retrospectively analyzed. Of the 61 study subjects, 7 (11.5%) were identified to have pulmonary toxicity and 2 (3.3%) died of pulmonary fibrosis progression despite aggressive treatment and the use of a multidisciplinary approach. No factor predisposing pulmonary toxicity was identified. Initial symptoms were non-specific, but bronchiolitis obliterans organizing pneumonia and interstitial pneumonitis were characteristic findings by high-resolution computed tomography of the chest. The benefit of steroid therapy was uncertain and was associated with steroid-induced diabetes mellitus requiring insulin therapy in two patients. Fatal pulmonary toxicity is a major concern of a quick course NAC-VBP. In conclusion, these patients require special monitoring for bleomycin-induced pulmonary toxicity.

Entities:  

Keywords:  Bleomycin; Drug Toxicity; Neoadjuvant Therapy; Uterine Cervical Neoplasms

Mesh:

Substances:

Year:  2010        PMID: 20119577      PMCID: PMC2811291          DOI: 10.3346/jkms.2010.25.2.240

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  22 in total

1.  Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results.

Authors:  J E Sardi; A Giaroli; C Sananes; M Ferreira; A Soderini; A Bermudez; L Snaidas; S Vighi; N Gomez Rueda; G di Paola
Journal:  Gynecol Oncol       Date:  1997-10       Impact factor: 5.482

2.  Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer.

Authors:  T C Chang; C H Lai; J H Hong; S Hsueh; K G Huang; H H Chou; C J Tseng; C S Tsai; J T Chang; C T Lin; H H Chang; P J Chao; K K Ng; S G Tang; Y K Soong
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

3.  A phase II trial of neoadjuvant chemotherapy prior to radical hysterectomy and/or radiation therapy in the management of advanced carcinoma of the uterine cervix.

Authors:  J D Bloss; J A Lucci; P J DiSaia; A Manetta; M A Schiano; N Ramsinghani; M L Berman
Journal:  Gynecol Oncol       Date:  1995-10       Impact factor: 5.482

4.  'Quick course' neoadjuvant chemotherapy with cisplatin, bleomycin and vincristine in advanced cervical cancer.

Authors:  Kishor C Singh; Alka Agarwal; Sarla Agarwal; Shalini Rajaram; Neerja Goel; Neera Agarwal
Journal:  Gynecol Obstet Invest       Date:  2004-06-08       Impact factor: 2.031

Review 5.  Chemotherapy-induced lung disease.

Authors:  Andrew H Limper
Journal:  Clin Chest Med       Date:  2004-03       Impact factor: 2.878

6.  A phase II trial of mitomycin, vincristine, bleomycin, and cisplatin (MOBP) as neoadjuvant therapy in high-risk cervical carcinoma.

Authors:  S A Weiner; S Aristizabal; D S Alberts; E A Surwit; K Deatherage-Deuser
Journal:  Gynecol Oncol       Date:  1988-05       Impact factor: 5.482

7.  Preoperative adjuvant chemotherapy in the treatment of cervical cancer stage Ib, IIa, and IIb with bulky tumor.

Authors:  D S Kim; H Moon; Y Y Hwang; S H Cho
Journal:  Gynecol Oncol       Date:  1988-03       Impact factor: 5.482

Review 8.  Pulmonary toxicity of antineoplastic therapy.

Authors:  H Kreisman; N Wolkove
Journal:  Semin Oncol       Date:  1992-10       Impact factor: 4.929

9.  Prognostic value of age and histologic type in neoadjuvant chemotherapy plus radical surgery for bulky (>/=4 cm) stage IB and IIA cervical carcinoma.

Authors:  H-J Huang; T-C Chang; J-H Hong; C-J Tseng; H-H Chou; K-G Huang; C-H Lai
Journal:  Int J Gynecol Cancer       Date:  2003 Mar-Apr       Impact factor: 3.437

10.  Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours.

Authors:  A B Simpson; J Paul; J Graham; S B Kaye
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

View more
  2 in total

Review 1.  Drug-Induced Interstitial Lung Disease: A Systematic Review.

Authors:  Sarah Skeoch; Nicholas Weatherley; Andrew J Swift; Alexander Oldroyd; Christopher Johns; Conal Hayton; Alessandro Giollo; James M Wild; John C Waterton; Maya Buch; Kim Linton; Ian N Bruce; Colm Leonard; Stephen Bianchi; Nazia Chaudhuri
Journal:  J Clin Med       Date:  2018-10-15       Impact factor: 4.241

Review 2.  Electrical stimulation on adverse events caused by chemotherapy in patients with cervical cancer: A protocol for a systematic review of randomized controlled trial.

Authors:  Peng-Hui Dou; Dan-Feng Zhang; Cui-Hong Su; Xiao-Li Zhang; Ying-Jie Wu
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.